Compare Stocks

Enter up to five stock symbols separated by a comma or space (ex. BAC,WFC,JPM,LON:BARC).
Date Range: 

 USANA Health SciencesSundial GrowersAurora CannabisHEXOChromaDex
SymbolNYSE:USNANASDAQ:SNDLNYSE:ACBNYSE:HEXONASDAQ:CDXC
Price Information
Current Price$100.67$0.94$8.19$5.60$7.96
52 Week RangeBuySellHoldHoldBuy
MarketRank™
Overall Score2.01.01.51.11.3
Analysis Score3.50.73.82.03.5
Community Score2.23.02.32.12.4
Dividend Score0.00.00.00.00.0
Ownership Score1.70.00.00.80.0
Earnings & Valuation Score2.51.31.30.60.6
Analyst Ratings
Consensus RecommendationBuySellHoldHoldBuy
Consensus Price Target$126.00$0.73$10.93$4.18$14.33
% Upside from Price Target25.16% upside-22.00% downside33.41% upside-25.45% downside80.07% upside
Trade Information
Market Cap$2.08 billion$1.56 billion$1.62 billion$685.92 million$531.39 million
Beta0.987.013.441.411.49
Average Volume114,843474,309,00021,026,7716,656,2233,309,679
Sales & Book Value
Annual Revenue$1.06 billion$75.86 million$207.89 million$60.46 million$46.29 million
Price / Sales1.9620.587.8011.3411.48
Cashflow$7.28 per shareN/AN/AN/AN/A
Price / Cash13.82N/AN/AN/AN/A
Book Value$16.25 per share$1.56 per share$13.73 per share$3.43 per share$0.34 per share
Price / Book6.200.600.601.6323.41
Profitability
Net Income$100.53 million$-204,570,000.00$-2,468,190,000.00$-406,370,000.00$-32,150,000.00
EPS$4.41($3.17)($2.86)($0.96)($0.52)
Trailing P/E Ratio18.64N/AN/AN/AN/A
Forward P/E Ratio18.47N/AN/AN/AN/A
P/E Growth0.96N/AN/AN/AN/A
Net Margins10.57%-415.89%-1,238.94%-517.61%-39.86%
Return on Equity (ROE)32.91%-187.67%-16.32%-13.15%-100.14%
Return on Assets (ROA)22.26%-72.67%-13.12%-10.35%-50.35%
Dividend
Annual PayoutN/AN/AN/AN/AN/A
Dividend YieldN/AN/AN/AN/AN/A
Three-Year Dividend GrowthN/AN/AN/AN/AN/A
Payout RatioN/AN/AN/AN/AN/A
Years of Consecutive Dividend GrowthN/AN/AN/AN/AN/A
Debt
Debt-to-Equity RatioN/A0.66%0.17%0.14%N/A
Current Ratio2.40%0.85%1.88%5.31%2.36%
Quick Ratio1.91%0.50%1.07%3.85%1.51%
Ownership Information
Institutional Ownership Percentage54.12%3.32%11.86%35.26%24.74%
Insider Ownership Percentage45.40%N/AN/AN/A12.92%
Miscellaneous
Employees1,9433942,731N/A110
Shares Outstanding20.62 million1.66 billion197.98 million122.49 million66.76 million
Next Earnings Date4/27/2021 (Confirmed)5/21/2021 (Estimated)5/13/2021 (Estimated)6/10/2021 (Estimated)5/10/2021 (Estimated)
OptionableOptionableNot OptionableOptionableOptionableOptionable
SourceHeadline
ChromaDex Hits Consumer Brand Marketing Sweet Spot With Former Nestle Executive In Charge - HBW InsightChromaDex Hits Consumer Brand Marketing Sweet Spot With Former Nestle Executive In Charge - HBW Insight
hbw.pharmaintelligence.informa.com - April 19 at 9:57 PM
Growth Drivers of D-Tagatose Market with Relevancy Mapping by Key Player like Nunaturals, Damhert Nutrition, ChromaDex, CJ Cheiljedang Corporation, Sigma-Aldrich Co. LLC., Alfa Aesar, and more | Forecast 2021-2026 - Los Hijos de la MalincheGrowth Drivers of D-Tagatose Market with Relevancy Mapping by Key Player like Nunaturals, Damhert Nutrition, ChromaDex, CJ Cheiljedang Corporation, Sigma-Aldrich Co. LLC., Alfa Aesar, and more | Forecast 2021-2026 - Los Hijos de la Malinche
loshijosdelamalinche.com - April 19 at 11:56 AM
ChromaDex Appoints Fadi Karam as Chief Marketing Officer - Valdosta Daily TimesChromaDex Appoints Fadi Karam as Chief Marketing Officer - Valdosta Daily Times
valdostadailytimes.com - April 19 at 11:56 AM
ChromaDex: An Anti-Aging Company With Major New Deals - Seeking AlphaChromaDex: An Anti-Aging Company With Major New Deals - Seeking Alpha
seekingalpha.com - April 19 at 6:56 AM
ChromaDex Appoints Fadi Karam as Chief Marketing Officer - Business WireChromaDex Appoints Fadi Karam as Chief Marketing Officer - Business Wire
businesswire.com - April 19 at 6:56 AM
ChromaDex Appoints Fadi Karam as Chief Marketing OfficerChromaDex Appoints Fadi Karam as Chief Marketing Officer
finance.yahoo.com - April 19 at 6:56 AM
ChromaDex Corporation (NASDAQ:CDXC) 15.03% up over a week, Can The Stock Hit well above $9.65-1?ChromaDex Corporation (NASDAQ:CDXC) 15.03% up over a week, Can The Stock Hit well above $9.65-1?
marketingsentinel.com - April 18 at 12:41 PM
ChromaDex Co. (NASDAQ:CDXC) Expected to Post Quarterly Sales of $16.47 MillionChromaDex Co. (NASDAQ:CDXC) Expected to Post Quarterly Sales of $16.47 Million
americanbankingnews.com - April 17 at 3:30 AM
-$0.09 EPS Expected for ChromaDex Co. (NASDAQ:CDXC) This Quarter-$0.09 EPS Expected for ChromaDex Co. (NASDAQ:CDXC) This Quarter
americanbankingnews.com - April 15 at 4:30 PM
ChromaDex (NASDAQ:CDXC) Stock Price Down 4.4%ChromaDex (NASDAQ:CDXC) Stock Price Down 4.4%
americanbankingnews.com - April 14 at 1:42 PM
Should You Think About Buying ChromaDex Corporation (NASDAQ:CDXC) Now? - NasdaqShould You Think About Buying ChromaDex Corporation (NASDAQ:CDXC) Now? - Nasdaq
nasdaq.com - April 11 at 1:20 PM
Where Will Chromadex Corp (CDXC) Stock Go Next After It Has Risen 14.43% in a Week? - InvestorsObserverWhere Will Chromadex Corp (CDXC) Stock Go Next After It Has Risen 14.43% in a Week? - InvestorsObserver
investorsobserver.com - April 7 at 1:36 PM
ChromaDex (NASDAQ:CDXC) Stock Price Down 4.2%ChromaDex (NASDAQ:CDXC) Stock Price Down 4.2%
americanbankingnews.com - April 6 at 12:02 PM
Elysium Sued ChromaDex For Sham FDA Petition SDNY Now Motion to Compel Denied - Inner City PressElysium Sued ChromaDex For Sham FDA Petition SDNY Now Motion to Compel Denied - Inner City Press
innercitypress.com - April 5 at 11:40 PM
Where Does Chromadex Corp (CDXC) Stock Fall in the Biotechnology Field After It Has Gained 21.95% This Week? - InvestorsObserverWhere Does Chromadex Corp (CDXC) Stock Fall in the Biotechnology Field After It Has Gained 21.95% This Week? - InvestorsObserver
investorsobserver.com - April 5 at 11:40 PM
ChromaDex inks research collaboration in citrin deficiency - Seeking AlphaChromaDex inks research collaboration in citrin deficiency - Seeking Alpha
seekingalpha.com - March 31 at 11:58 PM
ChromaDex and the Citrin Foundation Announce Global Research Collaboration Exploring Citrin Deficiency - BioSpaceChromaDex and the Citrin Foundation Announce Global Research Collaboration Exploring Citrin Deficiency - BioSpace
biospace.com - March 31 at 11:58 PM
ChromaDex (CDXC) and the Citrin Foundation Announce Global Research Collaboration Exploring Citrin Deficiency - StreetInsider.comChromaDex (CDXC) and the Citrin Foundation Announce Global Research Collaboration Exploring Citrin Deficiency - StreetInsider.com
streetinsider.com - March 31 at 1:57 PM
ChromaDex (NASDAQ:CDXC) Stock Price Up 8.4%ChromaDex (NASDAQ:CDXC) Stock Price Up 8.4%
americanbankingnews.com - March 31 at 1:26 PM
ChromaDex and the Citrin Foundation Announce Global Research Collaboration Exploring Citrin Deficiency - Business WireChromaDex and the Citrin Foundation Announce Global Research Collaboration Exploring Citrin Deficiency - Business Wire
businesswire.com - March 31 at 8:57 AM
ChromaDex and the Citrin Foundation Announce Global Research Collaboration Exploring Citrin DeficiencyChromaDex and the Citrin Foundation Announce Global Research Collaboration Exploring Citrin Deficiency
finance.yahoo.com - March 31 at 8:57 AM
ChromaDex Co. (NASDAQ:CDXC) Short Interest UpdateChromaDex Co. (NASDAQ:CDXC) Short Interest Update
americanbankingnews.com - March 31 at 8:28 AM
Zacks: Brokerages Expect ChromaDex Co. (NASDAQ:CDXC) Will Announce Quarterly Sales of $16.47 MillionZacks: Brokerages Expect ChromaDex Co. (NASDAQ:CDXC) Will Announce Quarterly Sales of $16.47 Million
americanbankingnews.com - March 30 at 11:06 AM
 Analysts Anticipate ChromaDex Co. (NASDAQ:CDXC) Will Post Earnings of -$0.09 Per Share Analysts Anticipate ChromaDex Co. (NASDAQ:CDXC) Will Post Earnings of -$0.09 Per Share
americanbankingnews.com - March 29 at 12:20 AM
Is Now An Opportune Moment To Examine ChromaDex Corporation (NASDAQ:CDXC)? - Yahoo FinanceIs Now An Opportune Moment To Examine ChromaDex Corporation (NASDAQ:CDXC)? - Yahoo Finance
finance.yahoo.com - March 28 at 2:22 PM
DateCompanyBrokerageAction
2/10/2021USANA Health SciencesRoth CapitalBoost Price Target
5/12/2020USANA Health SciencesTigress FinancialReiterated Rating
8/22/2019USANA Health SciencesJefferies Financial GroupInitiated Coverage
7/24/2019USANA Health SciencesPivotal ResearchReiterated Rating
7/3/2019USANA Health SciencesSidotiDowngrade
3/19/2021Sundial GrowersCanaccord GenuityDowngrade
3/16/2021Sundial GrowersCantor FitzgeraldInitiated Coverage
3/16/2021Sundial GrowersBMO Capital MarketsReiterated Rating
11/12/2020Sundial GrowersAtb Cap MarketsDowngrade
8/17/2020Sundial GrowersCIBCUpgrade
2/24/2020Sundial GrowersCowenDowngrade
9/27/2019Sundial GrowersBarclaysInitiated Coverage
2/12/2021Aurora CannabisMKM PartnersDowngrade
2/12/2021Aurora CannabisNeedham & Company LLCDowngrade
2/12/2021Aurora CannabisDesjardinsDowngrade
11/11/2020Aurora CannabisStifel NicolausDowngrade
7/1/2020HEXOBryan, Garnier & CoDowngrade
6/11/2020HEXOOppenheimerReiterated Rating
6/1/2020HEXOAlliance Global PartnersReiterated Rating
3/31/2020HEXOBank of AmericaInitiated Coverage
3/22/2021ChromaDexHC WainwrightBoost Price Target
3/8/2021ChromaDexB. RileyBoost Price Target
(Data available from 4/20/2018 forward. View 10+ years of historical ratings with our analyst ratings screener.)
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.